. 2010 Dec 22;36(4):887–895. doi: 10.1038/npp.2010.228

Table 1. In Vitro Estimates of D₂/D₃ Selectivity of Antipsychotics and the Predicted Occupancy at D₃ Receptors at Clinically Effective Levels of D₂ Receptor Blockade Based on Previous Reports (Levant, 1997; Schotte et al, 1996).

Antipsychotic	No. of studies	D₂ : D₃ Selectivity±SD	D₂ Occupancy	Predicted D₃ occupancy
Clozapine	9	2.82±2.01	60%	35%
Haloperidol	11	3.03±4.42	75%	50%
Risperidone	3	4.9±3.71	75%	38%
Olanzapine	1	3.18	75%	49%
Amisulpride 230 mg	3	2.29±0.58	67%	47%
Amisulpride 670 mg	3	2.29±0.58	80%	64%
Raclopride	3	1.16±0.53	—	—

D₂, and predicted D₃, occupancies are for illustrative purposes and are intended to reflect the normal therapeutic range for each compound. The calculation suggests that D₃ occupancy should range from 1/2 to 2/3 of D₂ occupancy at these levels of D₂ occupancy.

Table 1. In Vitro Estimates of D2/D3 Selectivity of Antipsychotics and the Predicted Occupancy at D3 Receptors at Clinically Effective Levels of D2 Receptor Blockade Based on Previous Reports (Levant, 1997; Schotte et al, 1996).

Table 1. In Vitro Estimates of D₂/D₃ Selectivity of Antipsychotics and the Predicted Occupancy at D₃ Receptors at Clinically Effective Levels of D₂ Receptor Blockade Based on Previous Reports (Levant, 1997; Schotte et al, 1996).